A photo of Daniel Starczynowski.

Daniel T. Starczynowski, PhD

  • Institute Associate Director, Cancer and Blood Diseases Institute
  • Member, Division of Experimental Hematology and Cancer Biology
  • Co-Leader, Hematologic Malignancies Program
  • Co-Chief Scientific Officer, Innovations Ventures
  • Associate Director for Basic Sciences, UC Cancer Center
  • Katherine Stewart Waters Endowed Chair of Hematologic Malignancies
  • Professor, UC Department of Pediatrics
Visit the Starczynowski LabMy Lab
Visit the Starczynowski Lab
Visit the Starczynowski LabVisit the Starczynowski Lab

About

Biography

Daniel T. Starczynowski, PhD, received his PhD in molecular biology from Boston University. He studied the NF-kB family of transcription factors and their role in B-cell lymphomas. During his postdoctoral fellowship at the BC Cancer Research Center, Dr. Starczynowski identified and characterized novel candidate genes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Following his postdoctoral training, Dr. Starczynowski joined the faculty at Cincinnati Children’s Hospital Medical Center and at the University of Cincinnati as an Assistant Professor. Dr. Starczynowski’s laboratory investigates the molecular and cellular basis of hematologic malignancies with the goal to advance novel therapeutic strategies.

BS: Fairleigh Dickinson University, Teaneck, NJ, 2000.

PhD: Boston University, Boston, MA, 2006.

Postdoctoral Fellow: University of British Columbia/BC Cancer Research Centre, Vancouver, Canada, 2010.

Research Areas

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Inflammation and Tolerance

Publications

In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Laranjeira, AB A; Kong, T; Snyder, SC; Fulbright, MC; Fisher, DA C; Starczynowski, DT; Oh, ST. Blood. 2024; 143:blood.2023022804.

Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Matsui, S; Ri, C; Bolanos, LC; Choi, K; Shibamiya, A; Ishii, A; Takaishi, K; Oshima-Hasegawa, N; Tsukamoto, S; Takeda, Y; Yokote, K; Starczynowski, DT; Sakaida, E; Muto, T. Leukemia. 2024; 38:1032-1045.

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms. Riabov, V; Xu, Q; Schmitt, N; Streuer, A; Ge, G; Bolanos, L; Wunderlich, M; Jann, JC; Wein, A; Altrock, E; Steiner, L; Jawhar, M; Hofmann, WK; Nowak, D. Haematologica: the hematology journal. 2024; 109:1426-1438.

Abstract 1464: Smoking carcinogen-induced inflammation promotes lung carcinogenesis via IRAK4 activation. Aggarwal, RK; Sidoli, S; Sahu, S; Aluri, S; Vegivinti, C; Verma, D; Gordon-Mitchell, S; Agarwal, B; Verma, T; Starczynowski, DT; LaFave, LM; Cheng, H; Verma, A; Zou, Y. Cancer Research. 2024; 84:1464.

Abstract 3092: MICRO-TAG: A novel fluorescence-based real-time cellular target engagement platform for drug discovery. Babic, I; Bryan, N; Cunningham, C; Sampson, A; Starczynowski, D; Nurmemmedov, E. Cancer Research. 2024; 84:3092.

UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies. Ishikawa, C; Barreyro, L; Sampson, A; Hueneman, K; Choi, K; Bolanos, LC; Volk, A; Watowich, SS; Greis, K; Starczynowski, DT. Blood. 2023; 142:2762.

The Mechanism of Therapy Resistance By Lineage Plasticity in AML and How to Overcome It. Walulik, S; Dean, S; Vick, EJ; Zhu, X; Wunderlich, M; Chou, C; Choi, K; Grimes, HL; Starczynowski, DT; Miles, LA; Volk, A. Blood. 2023; 142:1410.

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML. Elgamal, OA; Zapata, JC; Li, H; Sharpe, C; Fobare, S; Stearns, B; Lerma, JR; Bryant, K; Furby, C; Long, M; Burd, A; Pauza, CD; Hertlein, EK; Byrd, JC. Blood. 2023; 142:1544.

The Zymogen Form of Caspase-1 Is Required to Fine Tune Excessive Cell-Intrinsic Inflammation in Acute Myeloid Leukemia. Uible, EE; Choi, K; Hueneman, K; Bolanos, LC; Greis, K; Starczynowski, DT. Blood. 2023; 142:1391.

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients. Rosenbaum, JS; Kolt, AS; Hoyt, SB; Hayes, GM; Soldo, BL; Thomas, CJ; Starczynowski, DT. Blood. 2023; 142:4152.

Give Today

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026

© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.

U.S. News & World Report Honor Roll Badge for Top Children's Hospital.Best Places to Work.America's Best Large Employers